Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker LGST, is a clinical-stage biopharmaceutical company focused on T cell-based immunotherapies targeting infectious diseases and oncology. The company reached its current public structure through a de-SPAC merger with Logistics Innovation Technologies Corp., a blank-check vehicle that completed its IPO in 2021 in the healthcare and life sciences sector. The August 2023 10-Q filing, carrying accession number 0001493152-23-029606, reflects Tevogen Bio's post-combination operating entity as it advances its proprietary T cell therapy platform through clinical development. The company operates within the biotechnology industry. For complete filing history, sponsor details, and deal analytics on LGST and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.